iCAD, Inc. (ICAD)
| Market Cap | 91.66M |
| Revenue (ttm) | 32.52M |
| Net Income (ttm) | -13.15M |
| Shares Out | 25.18M |
| EPS (ttm) | -0.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 169,873 |
| Open | 3.68 |
| Previous Close | 3.63 |
| Day's Range | 3.43 - 3.74 |
| 52-Week Range | 2.91 - 19.00 |
| Beta | 1.28 |
| Analysts | Buy |
| Price Target | 14.45 (+297.0%) |
| Earnings Date | May 11, 2022 |
About ICAD
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calci...
Financial Performance
In 2021, iCAD, Inc.'s revenue was $33.64 million, an increase of 13.27% compared to the previous year's $29.70 million. Losses were -$11.25 million, -36.14% less than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ICAD stock is "Buy." The 12-month stock price forecast is 14.45, which is an increase of 296.98% from the latest price.
News
New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Li...
Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population...
iCAD to Present at the Spring Into Action - Best Ideas Virtual Investor Conference on May 17th, 2022
NASHUA, NH / ACCESSWIRE / May 12, 2022 / iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will presen...
Icad (ICAD) Reports Q1 Loss, Tops Revenue Estimates
Icad (ICAD) delivered earnings and revenue surprises of -40% and 0.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
iCAD Reports Financial Results for First Quarter Ended March 31, 2022
Company to host conference call and webcast today at 4:30 PM ET Company to host conference call and webcast today at 4:30 PM ET
iCAD to Report First Quarter 2022 Financial Results on Wednesday, May 11
NASHUA, N.H., April 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will r...
iCAD Showcases Innovative Breast Health Solutions Platform at National Consortium of Breast Centers (NCoBC) 31st Annu...
iCAD's award winning portfolio of breast health solutions to be featured at inaugural Pink Paradigm Summit, uniting clinical and advocacy leadership iCAD's award winning portfolio of breast health solut...
iCAD to Present at the 32nd Annual Oppenheimer Healthcare Conference
NASHUA, N.H., March 09, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company wi...
Icad (ICAD) Reports Q4 Loss, Lags Revenue Estimates
Icad (ICAD) delivered earnings and revenue surprises of -54.55% and 0.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2021
Launched ProFound AI® Risk, the world's first clinical decision support tool for short term breast cancer risk estimation
Analysts Estimate Icad (ICAD) to Report a Decline in Earnings: What to Look Out for
Icad (ICAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
iCAD to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28
NASHUA, N.H., Feb. 14, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will re...
iCAD's Breast AI Platform Earns U.S. Department of Defense Authorization to Operate
Leading-edge breast cancer detection platform meets stringent U.S. government security thresholds required for use across military healthcare facilities Leading-edge breast cancer detection platform mee...
iCAD Announces the Appointment of New Members to its Board of Directors
Dana Brown and Timothy Norris Irish offer extensive experience in technology, women's breast health and unique global perspectives Dana Brown and Timothy Norris Irish offer extensive experience in techn...
7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now
These cheap stocks under $10 are poised to rally in the new, more friendly macro environment that's in place as 2022 unfolds. The post 7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now appeared f...
iCAD to Participate at the 11th Annual LifeSci Partners Virtual Corporate Access Event
Company's President and incoming CEO to participate in a panel discussion titled “Med Tech / Digital Tools: What's the Mindset for 2022?” on January 5, 2022 at 2:00 pm ET Company's President and incomin...
First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States
Treatment marks initiation of international multicenter trial evaluating targeted radiation therapy and bevacizumab for the treatment of the most common and aggressive type of malignant brain tumor
iCAD to Participate at the Imagine AI + Healthcare Investor Summit
NASHUA, N.H., Dec. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Ste...
iCAD Announces CEO Transition
Stacey Stevens Appointed as President and CEO and will Join the Board of Directors in 2022, Michael Klein to remain Chairman of iCAD Board Stacey Stevens Appointed as President and CEO and will Join the...
iCAD to Participate in the 12th Annual Craig-Hallum Alpha Select Conference
NASHUA, N.H., Nov. 11, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will pa...
Icad (ICAD) Reports Q3 Loss, Misses Revenue Estimates
Icad (ICAD) delivered earnings and revenue surprises of 0.00% and -0.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Icad (ICAD) Q3 Earnings Expected to Decline
Icad (ICAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
iCAD Unveils Next Generation Technologies at Journées Francophones de Radiologie (October 8-11, Paris, France)
Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions
iCAD Launches Revolutionary Short-term Personalized Risk Assessment Solution for 3D Mammography
Latest generation of ProFound AI Risk offers greater accuracy and ethnically inclusive precision screening
iCAD to Host Educational Roundtable to Help Clinicians and Facilities Recover from COVID-19 Impact
Leading experts to discuss novel AI technology helping them overcome pandemic-related challenges including substantial mammography backlog Leading experts to discuss novel AI technology helping them ove...